Oppenheimer Downgrades INSYS Therapeutics (INSY) to Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts INSY Hot Sheet
Price: $0.29 --0%
Rating Summary:
4 Buy, 2 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 24 | New: 12
Rating Summary:
4 Buy, 2 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 24 | New: 12
Join SI Premium – FREE
Oppenheimer downgraded INSYS Therapeutics (NASDAQ: INSY) from Outperform to Perform and removed its price target (prior $40.00).
For an analyst ratings summary and ratings history on INSYS Therapeutics click here. For more ratings news on INSYS Therapeutics click here.
Shares of INSYS Therapeutics closed at $41.52 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- KeyBanc Downgrades Vistra Energy (VST) to Sector Weight
- Keefe, Bruyette & Woods Downgrades CleanSpark Inc. (CLSK) to Market Perform
- Barclays Downgrades Driven Brands (DRVN) to Underweight
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
